Neural Dev
T2D is a chronic metabolic disorder that can remain undetected for a number of years
[CrossRef] [PubMed] [Google Scholar] Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental
However, discontinuation is often followed by partial weight regain within months, reinforcing that patients generally experience these medicines as chronic therapies rather than short term cures
Cortisol increases blood sugar, promotes fat storage particularly around the abdomen, increases appetite for high-calorie foods, disrupts sleep, and impairs gut function all factors that GLP-1 medication is working to improve
Blocking activin type II receptors (ActRII) signaling by monoclonal antibody Bimagrumab combined with GLP-1 RA Semaglutide can reduce fat mass while potentially preserving lean mass- although this remains controversial (Nunn et al